Sarepta Therapeutics | SRPT - Pre Tax Profit


Sarepta Therapeutics reported $-1.75M in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amgen USD 2.08B 570M Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Daiichi Sankyo JPY -6.52B 113.25B Mar/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
Incyte USD 751.51M 407.91M Jun/2026
Insmed USD -11.37M 150.72M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Moderna USD -1.33B 535M Mar/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD -653M 5.84B Jun/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR 837M 1.17B Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Tectonic Therapeutic USD -18.97M 63K Dec/2025
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026